| Literature DB >> 33806618 |
Carina Becerril1, Martha Montaño1, José Cisneros2, Criselda Mendoza-Milla1, Annie Pardo3, Blanca Ortiz-Quintero4, Moisés Selman5, Carlos Ramos1.
Abstract
. In passages above ten and growing very actively, we observed that some human lung fibroblasts cultured under standard conditions were transformed into a lineage of epithelial-like cells (ELC). To systematically evaluate the possible mesenchymal-epithelial transition (MET) occurrence, fibroblasts were obtained from normal lungs and also from lungs affected by idiopathic interstitial diseases. When an unusual epithelial-like phenotypic change was observed, cultured cells were characterized by confocal immunofluorescence microscopy, immunoblotting, immunocytochemistry, cytofluorometry, gelatin zymography, RT-qPCR, and hybridization in a whole-transcript human microarray. Additionally, microvesicles fraction (MVs) from ELC and fibroblasts were used to induce MET, while the microRNAs (miRNAs) contained in the MVs were identified. Pattern-gene expression of the original fibroblasts and the derived ELC revealed profound changes, upregulating characteristic epithelial-cell genes and downregulating mesenchymal genes, with a marked increase of E-cadherin, cytokeratin, and ZO-1, and the loss of expression of α-SMA, collagen type I, and Thy-1 cell surface antigen (CD90). Fibroblasts, exposed to culture media or MVs from the ELC, acquired ELC phenotype. The miRNAs in MVs shown six expressed exclusively in fibroblasts, and three only in ELC; moreover, twelve miRNAs were differentially expressed between fibroblasts and ELC, all of them but one was overexpressed in fibroblasts. These findings suggest that the MET-like process can occur in human lung fibroblasts, either from normal or diseased lungs. However, the biological implication is unclear.Entities:
Keywords: E-cadherin; collagen type I; epithelial-like cell; fibroblast; mesenchymal–epithelial transition; microRNA; α-smooth muscle actin
Year: 2021 PMID: 33806618 PMCID: PMC8000192 DOI: 10.3390/biom11030378
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Human lung fibroblasts spontaneously convert into epithelial-like cells (ELC). Serial images of human lung fibroblasts (passage > 10) cultured on coverslips in standard culture technique. Some cells exhibiting an epithelial-like phenotype were observed, and up to 100% of cells showed the epithelial-like morphology could be detected. Cells grown on coverslips were fixed with acetone–methanol (2:1) and observed with phase-contrast microscopy (original magnification ×10). Fibroblasts showed the characteristic phenotype of fibroblasts and/or ELC. Original fibroblasts showing a fusiform and dispersed configuration (A). An area with typical fibroblasts and ~20% of ELC exhibiting the polygonal/cobblestone shaped, closely connected, and focally accumulated appearance (B). An area covered at 100 % of ELC, where fibroblasts are not apparent (C). F: fibroblast; ELC: epithelial-like cell.
Figure 2Human lung fibroblast when converted in ELC downregulated α-SMA and collagen type I, and concomitantly upregulated E-cadherin and cytokeratins. The expression of fibroblast and epithelial biomarkers analyzed by Western blotting showed that the change from a spindle to a polygonal/cobblestone shape was consistent with the marked downregulation of α-SMA and collagen type I (A), and the overexpression of E-cadherin, pancytokeratin (4, 5, 6, 8, 10, and 13 cytokeratin) (B). Three different cell lines were analyzed: two from ILD patients (lines F1/ELC-1; F-2/ELC-2), and two from brain dead patients (F-3/ELC-3; F3/ELC3). β-tubulin was used as a loading control. F: fibroblast; ELC: epithelial-like cell.
Figure 3Low α-SMA levels and high E-cadherin levels were detected during the epithelial–mesenchymal transition (EMT)-like process of fibroblasts by confocal immunofluorescence microscopy. Fibroblasts and ELC were grown on coverslips, fixed with paraformaldehyde, and stained with α-SMA and E-cadherin antibodies, followed by incubation with fluorescent dye-tagged secondary antibodies. Images show a sample containing approximately 20% fibroblasts and 80% ELC. DAPI was used to stain nuclei. α-SMA (green), E-cadherin (red), and nuclei (blue). Stained cells were visualized by confocal fluorescence microscopy (original magnification ×40). Differential interference contrast (DIC) is also shown.
Figure 4E-cadherin was increased in ELC derived from human lung fibroblasts. The fibroblast-rich culture plates obtained from different passages of the same cell line were compared with the correspondent ELC. The cells were fixed, labeled with an E-cadherin (CD324) antibody (PE-Cy5.5), and analyzed by cytofluorometry. Percentage of cells expressing E-cadherin in four different fibroblast and ELC lines (A): two were obtained from ILD patients (Line-1 and Line-2), and two from brain dead patients (Line-3 and Line-4). Representative scatter dot-plot images of flow cytometry for E-cadherin in fibroblasts and ELC (B). F: fibroblast; ELC: epithelial-like cell.
Figure 5Thy-1 cell surface antigen (CD90) was downregulated in lung fibroblasts after undergoing mesenchymal–epithelial transition (MET) and exhibited the ELC phenotype. Cells were fixed, labeled with a Thy-1 cell surface antigen antibody (APC; Sc-59398, Santa Cruz Biotechnology; 1:200 dilution) and analyzed by cytofluorometry. The percentage of fibroblasts and the derived ELC cells expressing Thy-1 cell surface antigen were examined in four different cell lines (A,B). Four different cell lines were analyzed: two derived from ILD patients (lines F1/ELC-1; F-2/ELC-2), and two from brain dead patients (F-3/ELC-3; F3/ELC3). F: fibroblast; ELC: epithelial-like cell. C and D: Representative scatter dot-plot images of flow cytometry for CD90 in fibroblasts (C) and epithelial-like cell (D).
Figure 6A gradual increase in the MMP-9 activity with a concomitant decrease in the MMP-2 activity is observed as more fibroblasts undergo MET in culture. Basal analysis of gelatinase activities analyzed by zymography in whole culture media from fibroblasts cultures containing different percentages of ELC (10–100%). Culture media from U2OS cells (epithelial cell line) was used as a control. F: fibroblasts; ELC: epithelial-like cells.
The 100 most upregulated genes expressed by ELC after the MET from human lung fibroblasts are listed. Fold change for each gene is indicated; symbol and gene name are in progressive order of expression.
| Fold Change | Symbol | Entrez Gene Name | Fold Change | Symbol | Entrez Gene Name |
|---|---|---|---|---|---|
| 8.39 | AKR1B10 | aldo-keto reductase family 1, member B10 | 4.83 | UPK1B | uroplakin 1B |
| 7.74 | SLCO1B3 | solute carrier organic anion transporter family member 1B3 | 4.83 | ST6GAL2 | ST6 beta-galactoside alpha-2,6-sialyltransferase 2 |
| 7.72 | CYP24A1 | cytochrome P450 family 24 subfamily A member 1 | 4.79 | TIMD4 | T cell immunoglobulin and mucin domain containing 4 |
| 7.5 | GPX2 | glutathione peroxidase 2 | 4.77 | TM4SF20 | transmembrane 4 L six family member 20 |
| 7.37 | CEACAM6 | CEA cell adhesion molecule 6 | 4.77 | CXADR | CXADR Ig-like cell adhesion molecule |
| 7.07 | KYNU | kynureninase | 4.76 | SMOC1 | SPARC related modular calcium binding 1 |
| 6.97 | PON3 | paraoxonase 3 | 4.71 | NR5A2 | nuclear receptor subfamily 5 group A member 2 |
| 6.76 | SPP1 | secreted phosphoprotein 1 | 4.67 | ANKRD18A | ankyrin repeat domain 18A |
| 6.64 | ABCC2 | ATP binding cassette subfamily C member 2 | 4.66 | CST1 | cystatin SN |
| 6.61 | CP | ceruloplasmin | 4.62 | TBC1D8 | TBC1 domain family member 8 |
| 6.55 | HAVCR1 | hepatitis A virus cellular receptor 1 | 4.59 | ACSM3 | acyl-CoA synthetase medium chain family member 3 |
| 6.44 | SLC27A2 | solute carrier family 27 member 2 | 4.56 | CLDN1 | claudin 1 |
| 6.44 | TNS4 | tensin 4 | 4.5 | ANO5 | anoctamin 5 |
| 6.42 | CNTN1 | contactin 1 | 4.49 | PLS1 | plastin 1 |
| 6.3 | HORMAD1 | HORMA domain containing 1 | 4.49 | ITGB6 | integrin subunit beta 6 |
| 6.2 | LGSN | lengsin, lens protein with glutamine synthetase domain | 4.48 | HNF1B | HNF1 homeobox B |
| 6.17 | HPGD | 15-hydroxyprostaglandin dehydrogenase | 4.46 | ARHGAP26 | Rho GTPase activating protein 26 |
| 6.08 | CEACAM7 | CEA cell adhesion molecule 7 | 4.46 | AKR1C1 | aldo-keto reductase family 1 member C1 |
| 6.07 | KRT81 | keratin 81 | 4.41 | ELOVL7 | ELOVL fatty acid elongase 7 |
| 6.06 | HGD | homogentisate 1,2-dioxygenase | 4.41 | SLPI | secretory leukocyte peptidase inhibitor |
| 6.06 | AKR1C3 | aldo-keto reductase family 1, member C3 | 4.41 | F5 | coagulation factor V |
| 5.87 | NTRK3 | neurotrophic receptor tyrosine kinase 3 | 4.37 | EHF | ETS homologous factor |
| 5.8 | AREG | anphiregulin | 4.34 | MLPH | melanophilin |
| 5.8 | KRTS | keratin 8 | 4.31 | HIST1H2AB | H2A clustered histone 4 |
| 5.75 | MMP7 | matrix metallopeptidase 7 | 4.31 | ELF3 | E74 like ETS transcription factor 3 |
| 5.7 | GCNT3 | glucosaminyl (N-acetyl) transferase 3, mucin type | 4.3 | CEACAM5 | CEA cell adhesion molecule 5 |
| 5.67 | AKR1C2 | aldo-keto reductase family 1, member C2 | 4.25 | WDR72 | WD repeat domain 72 |
| 5.66 | TM4SF18 | transmembrane 4 L six family member 18 | 4.23 | ITGB4 | integrin subunit beta 4 |
| 5.66 | SLC22A3 | solute carrier family 22 member 3 | 4.23 | MAP7 | microtubule associated protein 7 |
| 5.63 | CDH1 | cadherin 1 | 4.22 | FGB | fibrinogen beta chain |
| 5.52 | CDH17 | cadherin 17 | 4.21 | TESC | tescalcin |
| 5.46 | PPARGC1A | PPARG coactivator 1 alpha | 4.19 | NRCAM | neuronal cell adhesion molecule |
| 5.41 | HNF1A-AS1 | HNF1A antisense RNA 1 | 4.16 | IGFBP1 | insulin like growth factor binding protein 1 |
| 5.36 | GPRIN3 | GPRIN family member 3 | 4.15 | OAS1 | 2’-5’-oligoadenylate synthetase 1 |
| 5.31 | GABRB3 | gamma-aminobutyric acid type A receptor subunit beta3 | 4.11 | CDRT1 | CMT1A duplicated region transcript 1 |
| 5.31 | EREG | epiregulin | 4.09 | TFAP2A | transcription factor AP-2 alpha |
| 5.31 | TSPAN7 | tetraspanin 7 | 4.06 | TC2N | tandem C2 domains, nuclear |
| 5.29 | ARSE | arylsulfatase E | 4.06 | POF1B | POF1B actin binding protein |
| 5.2 | RAB27B | RAB27B, member RAS oncogene family | 4.04 | mir622 | microRNA 622 |
| 5.16 | SLC17A3 | solute carrier family 17 member 3 | 4.01 | MTUS1 | microtubule associated scaffold protein 1 |
| 5.13 | CYP4F11 | cytochrome P450 family 4 subfamily F member 11 | 3.99 | CPS1 | carbamoyl-phosphate synthase 1 |
| 5.13 | SLCO1B7 | solute carrier organic anion transporter family member 1B7 (putative) | 3.99 | FILIP1 | filamin A interacting protein 1 |
| 5.11 | RSPO3 | R-spondin 3 | 3.98 | CYP4F3 | cytochrome P450 family 4 subfamily F member 3 |
| 5.01 | FGL1 | fibrinogen-like 1 | 3.98 | FZD3 | frizzled class receptor 3 |
| 5 | AREG | amphiregulin | 3.98 | CHRNA5 | cholinergic receptor nicotinic alpha 5 subunit |
| 4.99 | ALDH3A1 | aldehyde dehydrogenase 3 family member A1 | 3.97 | KRT18 | keratin 18 |
| 4.98 | MUC13 | mucin 13, cell surface associated | 3.96 | KCNJ16 | potassium inwardly rectifying channel subfamily J member 16 |
| 4.86 | CLMN | calmin | 3.93 | GABRA5 | gamma-aminobutyric acid type A receptor subunit alpha5 |
| 4.85 | CA12 | carbonic anhydrase 12 | 3.93 | GRB14 | growth factor receptor bound protein 14 |
| 4.84 | TMEM156 | transmembrane protein 156 | 3.91 | INSL4 | insulin like 4 |
The 100 most downregulated genes expressed by ELC after the MET from human lung fibroblasts are listed. Fold change for each gene is indicated; symbol and gene name are in progressive order of expression.
| Fold Change | Symbol | Entrez Gene Name | Fold Change | Symbol | Entrez Gene Name |
|---|---|---|---|---|---|
| −8.32 | SPARC | secreted protein acidic and cysteine rich | −4.93 | JAM2 | junctional adhesion molecule 2 |
| −7.5 | SERPINB2 | serpin family B member 2 | −4.92 | FLNC | filamin C |
| −7.3 | POSTN | periostin | −4.92 | COL3A1 | collagen type III alpha 1 chain |
| −7.24 | LOX | lysyl oxidase | −4.92 | FMOD | fibromodulin |
| −7.15 | DCN | decorin | −4.9 | XYLT1 | xylosyltransferase 1 |
| −6.95 | SULF1 | sulfatase 1 | −4.88 | ENG | endoglin |
| −6.95 | IGFBP5 | insulin like growth factor binding protein 5 | −4.87 | PCDH18 | protocadherin 18 |
| −6.88 | LUM | lumican | −4.87 | MAN1A1 | mannosidase alpha class 1A member 1 |
| −6.82 | TIMP3 | TIMP metallopeptidase inhibitor 3 | −4.84 | TRPS1 | transcriptional repressor GATA binding 1 |
| −6.68 | FAP | fibroblast activation protein alpha | −4.83 | ZNF737 | zinc finger protein 737 |
| −6.51 | COL6A3 | collagen type VI alpha 3 chain | −4.83 | EGR1 | early growth response 1 |
| −6.5 | LAMA4 | laminin subunit alpha 4 | −4.81 | MIR145 | microRNA 145 |
| −6.46 | CDH11 | cadherin 11 | −4.81 | ARID5B | AT-rich interaction domain 5B |
| −6.23 | ZNF253 | zinc finger protein 253 | −4.8 | FAM26E | calcium homeostasis modulator family member 5 |
| −6.14 | THBS2 | thrombospondin 2 | −4.77 | HAS2 | hyaluronan synthase 2 |
| −6.11 | BGN | biglycan | −4.76 | IRAK3 | interleukin 1 receptor associated kinase 3 |
| −6.09 | CDH13 | cadherin 13 | −4.76 | LHFPL6 | LHFPL tetraspan subfamily member 6 |
| −6.01 | INHBA | inhibin subunit beta A | −4.7 | PDCD1LG2 | programmed cell death 1 ligand 2 |
| −5.96 | COL1A2 | collagen type I alpha 2 chain | −4.69 | TNFRSF11B | TNF receptor superfamily member 11b |
| −5.94 | MMP2 | matrix metallopeptidase 2 | −4.68 | ZNF83 | zinc finger protein 83 |
| −5.92 | SLIT2 | slit guidance ligand 2 | −4.67 | MMP14 | matrix metallopeptidase 14 |
| −5.9 | SNAI2 | snail family transcriptional repressor 2 | −4.67 | NDNF | neuron derived neurotrophic factor |
| −5.87 | FGF7 | fibroblast growth factor 7 | −4.65 | TNC | tenascin C |
| −5.76 | LY96 | lymphocyte antigen 96 | −4.63 | ANTXR2 | ANTXR cell adhesion molecule 2 |
| −5.76 | DPP4 | dipeptidyl peptidase 4 | −4.6 | FBN1 | fibrillin 1 |
| −5.64 | DDR2 | discoidin domain receptor tyrosine kinase 2 | −4.57 | PTGS1 | prostaglandin-endoperoxide synthase 1 |
| −5.61 | SERPINF1 | serpin family F member 1 | −4.55 | CRYAB | crystallin alpha B |
| −5.54 | EDIL3 | EGF like repeats and discoidin domains 3 | −4.53 | ITGB3 | integrin subunit beta 3 |
| −5.46 | GREM1 | gremlin 1, DAN family BMP antagonist | −4.51 | DSEL | dermatan sulfate epimerase like |
| −5.45 | ELTD1 | adhesion G protein-coupled receptor L4 | −4.5 | PDGFRB | platelet derived growth factor receptor beta |
| −5.43 | SERPING1 | serpin family G member 1 | −4.5 | EFEMP2 | EGF containing fibulin extracellular matrix protein 2 |
| −5.4 | DDR2 | discoidin domain receptor tyrosine kinase 2 | −4.50 | MMP3 | matrix metallopeptidase 3 |
| −5.4 | SLFN11 | schlafen family member 11 | −4.47 | KGFLP1 | fibroblast growth factor 7 pseudogene 6 |
| −5.38 | IFITM3 | interferon induced transmembrane protein 3 | −4.46 | LOC100288114 | Uncharacterized |
| −5.36 | DOK5 | docking protein 5 | −4.46 | ANGPTL2 | angiopoietin like 2 |
| −5.34 | CDK14 | cyclin dependent kinase 14 | −4.45 | IFITM1 | interferon induced transmembrane protein 1 |
| −5.31 | IL6 | interleukin 6 | −4.45 | ZFPM2 | zinc finger protein, FOG family member 2 |
| −5.29 | PDGFRA | platelet derived growth factor receptor alpha | −4.44 | ENPP2 | ectonucleotide pyrophosphatase/phosphodiesterase 2 |
| −5.24 | GLT8D2 | glycosyltransferase 8 domain containing 2 | −4.43 | EDNRA | endothelin receptor type A |
| −5.23 | PTGIS | prostaglandin I2 synthase | −4.41 | OLFML3 | olfactomedin like 3 |
| −5.21 | KIAA1199 | cell migration inducing hyaluronidase 1 | −4.37 | ADAMTS6 | ADAM metallopeptidase with thrombospondin type 1 motif 6 |
| −5.18 | PRRX1 | paired related homeobox 1 | −4.36 | EPB41L3 | erythrocyte membrane protein band 4.1 like 3 |
| −5.14 | WNT5A | Wnt family member 5A | −4.34 | PDE5A | phosphodiesterase 5A |
| −5.1 | PXDN | peroxidasin | −4.31 | MFAP4 | microfibril associated protein 4 |
| −5.06 | FLRT2 | fibronectin leucine rich transmembrane protein 2 | −4.31 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 |
| −5.06 | CDH6 | cadherin 6 | −4.3 | NEXN | nexilin F-actin binding protein |
| −5.01 | NID1 | nidogen 1 | −4.29 | SNORD113-4 | small nucleolar RNA, C/D box 113-4 |
| −4.97 | PAMR1 | peptidase domain containing associated with muscle regeneration 1 | −4.28 | DNAJC15 | DnaJ heat shock protein family (Hsp40) member C15 |
| −4.97 | MME | membrane metalloendopeptidase | −4.24 | ZEB2 | ZEB2 antisense RNA 1 |
| −4.94 | COL1A1 | collagen type I alpha 1 chain | −4.23 | FN1 | fibronectin 1 |
Figure 7Clustering analysis plot of fibroblasts (F) and derived ELC showing marked changes in pattern-gene expression, with downregulation of canonical TGF-β and Wnt pathways in the ELC derived from fibroblasts. Cluster analysis of fibroblasts and derived ELC. Upregulated and downregulated genes are represented in red and green colors, respectively (A). Pathway analysis was performed using ingenuity pathway analysis (IPA) software, as described in the Methods. Transcription factors Snail, Twist, and Zeb were downregulated (green), while E-cadherin was upregulated (B).
Figure 8Microvesicles (MVs) obtained from ELC induce the change to an epithelial-like phenotype in human normal lung fibroblasts. Representative immunoblot image to the CD63 protein in MVs purified from ECL from an IPF patient (A). MVs effect on E-cadherin expression analyzed by Western blotting: MVs purified from culture media obtained from human normal lung fibroblasts (NF; passage 4), IPF fibroblasts (IPF; passage 4), and ELC (passage 4). Total protein extract from A549 epithelial cell line was used as a positive control (B). Serial images of human lung fibroblasts incubated with MVs converted in ELC, observed with phase-contrast microscopy (original magnification ×10): area with 100% of normal lung fibroblasts (C). Image captured after 2 days exhibiting ~95% fibroblasts and ~5% ELC displaying a polygonal/cobblestone shaped, closely connected to each other and focally accumulated appearance (D). Image obtained after 4 days exhibiting ~90% fibroblasts and ~10% of ELC (E). Image acquired after 6 days showing ~65% fibroblasts and ~35% of ELC (F). Image taken after 8 days displaying ~40% fibroblasts and ~60% of ELC (G). Image obtained after 10 days displaying ~20% fibroblasts and ~80% ELC (H). Area covered at ~100% by ELC captured after 12 days of culture, where fibroblasts are not apparent (I).
The miRNAs overexpressed in MVs derived from fibroblasts compared with those from ELC. Fold changes are indicated (FC). F: fibroblast; ELC: epithelial-like cell.
| F vs. ELC | FC |
|---|---|
| hsa-let-7a-5p | 3.1 |
| hsa-let-7b-5p | 66.5 |
| hsa-let-7c | 4.4 |
| hsa-let-7d-5p | 19.7 |
| hsa-let-7e-5p | 5.2 |
| hsa-miR-21-3p | 8.1 |
| hsa-miR-23a-3p | 3.0 |
| hsa-miR-23b-3p | 4.9 |
| hsa-miR-24-2-5p | 2.2 |
| hsa-miR-26a-5p | 49.4 |
| hsa-miR-27a-3p | 16.8 |
|
| |
| hsa-miR-30b-5p | 2.4 |
Figure 9Similar fibroblasts to those converted in ELC showed characteristic biomarkers of fibroblast phenotype but not pancytokeratin. Normal lung fibroblasts (passage = 4; n = 3) were grown and seeded on coverslips, fixed, and labeled with antibodies for immunocytochemistry before being analyzed by cytofluorometry. Pancytokeratin (A), Thy-1 cell surface antigen (B), vimentin (C), type I collagen (D), PDGFRβ (E), secondary anti IgG antimouse alone, used as a negative control (F). Cell fluorometric analysis confirmed the absence of pancytokeratin (G), and the presence of PDGFRβ (H), and vimentin (I). Representative flow cytometry histograms showing the expression of pancytokeratin (negative) (G), PDGFRβ (positive) (H), and vimentin (positive) (H). Unshaded histogram corresponds to the staining control with the secondary antibodies alone.